Movement Alert｜Kodiak Sciences Inc. Overnight Rise 5.07%, Phase 3 eye-drug progress and major director share purchase remain in focus

On October 20, Kodiak Sciences Inc. rose 5.07% Overnight, trading at $95.98 per share, with turnover of $2124.73.

The clearest public catalyst remained the continued market reaction to two positive Phase 3 wet AMD updates and a large insider-backed purchase by director Felix Baker through Baker Bros. Advisors.

Previously disclosed results showed Zenkuda and tabirafusp-ted met primary endpoints in a late-stage wet AMD study, achieving non-inferiority in vision gains versus aflibercept over the first year, while 54% of patients maintained a six-month dosing interval under retreatment criteria. Separately, Baker Bros. Advisors bought about $157 million of shares at roughly $80.85 each, described as Felix Baker's largest single increase to date, lifting related ownership to about 35%. The company also plans to submit data from five positive Phase 3 Zenkuda studies to regulators in the fourth quarter, keeping upcoming clinical and regulatory milestones in view.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)